Your browser is no longer supported. Please, upgrade your browser.
Avid Bioservices, Inc.
Index- P/E141.09 EPS (ttm)0.13 Insider Own0.30% Shs Outstand61.41M Perf Week-12.25%
Market Cap1.14B Forward P/E56.00 EPS next Y0.33 Insider Trans-29.50% Shs Float60.77M Perf Month-33.65%
Income8.30M PEG9.41 EPS next Q0.04 Inst Own96.30% Short Float9.64% Perf Quarter-29.57%
Sales106.30M P/S10.72 EPS this Y120.80% Inst Trans-0.63% Short Ratio5.73 Perf Half Y-29.84%
Book/sh0.83 P/B21.93 EPS next Y21.27% ROA3.30% Target Price32.67 Perf Year27.72%
Cash/sh2.61 P/C6.96 EPS next 5Y15.00% ROE12.80% 52W Range12.60 - 34.51 Perf YTD-37.63%
Dividend- P/FCF142.48 EPS past 5Y31.60% ROI7.00% 52W High-47.26% Beta2.45
Dividend %- Quick Ratio2.70 Sales past 5Y16.70% Gross Margin32.90% 52W Low44.44% ATR1.50
Employees252 Current Ratio3.00 Sales Q/Q-43.90% Oper. Margin15.40% RSI (14)22.12 Volatility6.20% 6.26%
OptionableYes Debt/Eq2.77 EPS Q/Q-32.60% Profit Margin7.80% Rel Volume0.67 Prev Close18.51
ShortableYes LT Debt/Eq2.77 EarningsDec 07 AMC Payout0.00% Avg Volume1.02M Price18.20
Recom2.00 SMA20-26.35% SMA50-34.65% SMA200-26.20% Volume680,189 Change-1.67%
Dec-08-21Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Mar-17-21Initiated RBC Capital Mkts Outperform $21
Nov-10-20Initiated KeyBanc Capital Markets Overweight $12
Dec-10-19Upgrade First Analysis Sec Outperform → Strong Buy
Oct-17-19Initiated Stephens Overweight $8
Oct-16-19Initiated Craig Hallum Buy $11
Jun-28-19Upgrade Janney Neutral → Buy $10
May-09-19Downgrade Janney Buy → Neutral
Jan-21-22 06:15PM  
Jan-14-22 11:22AM  
Jan-10-22 08:05AM  
Jan-07-22 01:38PM  
Dec-30-21 04:51AM  
Dec-29-21 02:16PM  
Dec-21-21 06:41AM  
Dec-15-21 10:00AM  
Dec-09-21 11:55AM  
Dec-08-21 03:14AM  
Dec-07-21 11:30PM  
Dec-06-21 11:32AM  
Dec-03-21 11:58AM  
Dec-02-21 07:26PM  
Nov-30-21 04:05PM  
Nov-24-21 03:00PM  
Nov-04-21 08:05AM  
Oct-26-21 06:39PM  
Oct-25-21 06:58PM  
Oct-14-21 08:05AM  
Oct-07-21 08:05AM  
Oct-01-21 09:33AM  
Sep-14-21 10:00AM  
Sep-09-21 03:00PM  
Sep-08-21 04:05PM  
Sep-02-21 04:05PM  
Sep-01-21 04:05PM  
Aug-08-21 03:59AM  
Jul-29-21 12:19PM  
Jul-20-21 09:27AM  
Jul-01-21 08:05AM  
Jun-29-21 07:00PM  
Jun-24-21 02:05AM  
Jun-22-21 04:05PM  
Jun-04-21 04:36AM  
May-25-21 08:05AM  
May-21-21 09:55AM  
Apr-27-21 10:31AM  
Apr-25-21 04:20AM  
Apr-22-21 05:54PM  
Apr-15-21 04:05PM  
Apr-14-21 09:40AM  
Apr-07-21 08:29AM  
Apr-06-21 09:57AM  
Mar-23-21 09:24AM  
Mar-22-21 09:02AM  
Mar-17-21 08:05AM  
Mar-12-21 06:01AM  
Mar-10-21 12:20AM  
Mar-08-21 07:00PM  
Mar-03-21 04:05PM  
Mar-01-21 04:05PM  
Feb-23-21 11:57PM  
Feb-22-21 08:05AM  
Feb-18-21 01:08PM  
Feb-03-21 07:00AM  
Jan-26-21 11:21AM  
Jan-10-21 01:55AM  
Dec-15-20 08:51PM  
Dec-14-20 04:05PM  
Dec-10-20 09:00AM  
Dec-09-20 04:45PM  
Dec-07-20 04:05PM  
Dec-05-20 01:36AM  
Dec-03-20 11:03AM  
Dec-02-20 09:30PM  
Dec-01-20 04:05PM  
Nov-24-20 04:05PM  
Nov-08-20 08:20AM  
Nov-05-20 10:00AM  
Sep-24-20 09:29AM  
Sep-15-20 04:05PM  
Sep-10-20 10:29AM  
Sep-03-20 07:55AM  
Sep-02-20 07:25AM  
Sep-01-20 06:30PM  
Aug-31-20 04:05PM  
Aug-26-20 08:05AM  
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ziebell Mark RV. P., General CounselJan 10Sale21.583517,5747,775Jan 11 08:22 PM
Green Nicholas StewartPresident & CEOJan 10Sale21.583,21469,35725,468Jan 11 08:21 PM
Hart Daniel RChief Financial OfficerJan 10Sale21.5887718,92527,976Jan 11 08:22 PM
Ziebell Mark RV. P., General CounselJan 03Option Exercise12.7420,675263,47621,675Jan 05 07:56 PM
Hancock Richard BDirectorJan 03Option Exercise4.535,00022,65040,200Jan 05 07:53 PM
Hart Daniel RChief Financial OfficerJan 03Option Exercise5.665002,83027,833Jan 05 07:54 PM
Hancock Richard BDirectorJan 03Sale27.535,000137,64435,200Jan 05 07:53 PM
Hart Daniel RChief Financial OfficerJan 03Sale29.0750014,53527,333Jan 05 07:54 PM
Ziebell Mark RV. P., General CounselJan 03Sale27.6520,675571,6727,429Jan 05 07:56 PM
Ziebell Mark RV. P., General CounselDec 27Sale30.276,829206,6897,429Dec 29 07:23 PM
Ziebell Mark RV. P., General CounselDec 15Option Exercise3.296,42921,15120,687Dec 16 09:36 PM
Ziebell Mark RV. P., General CounselDec 15Sale24.576,429157,94514,258Dec 16 09:36 PM
Hancock Richard BDirectorDec 01Option Exercise4.535,00022,65037,821Dec 03 07:12 PM
Hancock Richard BDirectorDec 01Sale30.905,000154,50932,821Dec 03 07:12 PM
Hancock Richard BDirectorNov 15Option Exercise4.53135937,821Nov 17 07:29 PM
Hancock Richard BDirectorNov 15Sale32.475,000162,33332,821Nov 17 07:29 PM
Ziebell Mark RV. P., General CounselOct 11Sale22.373497,80814,258Oct 12 05:38 PM
Green Nicholas StewartPresident & CEOOct 11Sale22.372,78662,32522,639Oct 12 05:36 PM
Hart Daniel RChief Financial OfficerOct 11Sale22.3776017,00226,863Oct 12 05:36 PM
Green Nicholas StewartPresident & CEOAug 02Sale25.5618,701477,99819,852Aug 03 08:17 PM
Ziebell Mark RV. P., General CounselJul 12Sale25.617,207184,57413,911Jul 13 09:40 PM
Hart Daniel RChief Financial OfficerJul 12Sale25.615,409138,52826,103Jul 13 09:39 PM
Bamforth Mark RDirectorMar 17Buy18.18126,0002,290,680126,000Mar 19 05:25 PM
Bamforth Mark RDirectorMar 17Sale18.1826,000472,6800Mar 19 05:25 PM
Bamforth Mark RDirectorMar 17Sale18.18100,0001,818,0000Mar 19 05:25 PM